查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2012953

生物製藥物流市場：依產品類型、服務類型、運輸方式、溫度需求及最終用戶分類－2026-2032年全球市場預測

Bio-Pharmaceutical Logistics Market by Product Type, Service Type, Mode Of Transport, Temperature Requirement, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物製藥物流市場價值將達到 187.1 億美元，到 2026 年將成長至 206.9 億美元，到 2032 年將達到 407.7 億美元，複合年成長率為 11.76%。

主要市場統計數據
基準年 2025 187.1億美元
預計年份：2026年 206.9億美元
預測年份 2032 407.7億美元
複合年成長率 (%) 11.76%

對現代生物製藥物流格局進行深入分析，重點關注技術融合、監管收緊以及建立具有韌性的供應鏈所面臨的策略挑戰。

生物製藥物流領域正面臨著由科學進步、監管加強和地緣政治動態共同驅動的日益複雜的局面。運輸臨床實驗藥物、生技藥品、血液製品和疫苗的公司，在日益分散的全球網路中，對嚴格的溫度控制、可追溯性和合規性提出了更高的要求。因此，物流領導者必須平衡兩大挑戰：既要最大限度地降低產品完整性風險，也要維持分銷和臨床供應鏈的速度和成本效益。

溫度控制、監管整合、數位控制塔和永續發展壓力如何將生物製藥物流轉變為以產能為主導的服務模式。

在生物物流產業，正在發生多項變革性變化，重新定義了人們對物流速度、安全性和品質的期望。首先，溫控操作正從單純的合規要求轉變為策略性功能，相關人員要求提供涵蓋低溫、冷凍、冷藏和常溫要求的端到端低溫運輸保障。這種轉變不僅推動了對隔熱包裝和主動控制容器的投資，也推動了對即時遙測技術的投資，從而能夠提供整個運輸過程中的詳細可視性。

近期關稅趨勢的多方面累積影響正在重塑生物製藥物流領域的採購、運輸選擇、海關專業知識要求和區域基礎設施投資。

美國在2025年前逐步實施的關稅政策對生物製藥物流產生了累積影響，其影響範圍遠不止於表面的關稅稅率，還涵蓋了運輸路線選擇、供應商選擇和庫存管理等各個方面。不斷增加的關稅負擔推高了陸路運輸成本，促使企業重新評估其採購和運輸組合，以確保關鍵生產組件和成品生物製藥的供應。因此，許多相關人員正根據產品重要性和時間限制對供應鏈進行細分，試圖確定哪些貨運值得採用高價空運，哪些可以整合到成本較低的海運或鐵路運輸路線中。

詳細的細分分析揭示了服務範圍、運輸方式、溫度等級、產品類型和最終用戶期望如何共同決定營運需求和策略投資。

精細化的市場細分觀點揭示了不同服務類型、運輸方式、溫度等級、產品類型和最終用戶之間的不同需求模式、營運要求和商業機會。基於服務類型，該生態系統包括低溫運輸包裝、清關、貨運代理、倉儲和配送以及附加價值服務。附加價值服務本身包括配套服務、貼標服務和品質檢驗。這種功能分佈凸顯了供應商需要將技術處理能力與合規性和產品準備能力結合。依運輸方式分類，貨物可透過空運、鐵路、陸運和海運。每條路線在速度、成本和環境波動風險方面都存在權衡，因此需要針對每條路線制定最佳包裝策略和緊急時應對計畫。

美洲、歐洲、中東和非洲以及亞太地區在基礎設施投資、監管複雜性和臨床領域成長方面的差異，如何推動區域專業化和運輸能力的擴張。

區域趨勢正在塑造全部區域需求模式、基礎設施建設和監管協調方面的差異。在美洲，投資集中於擴大區域冷藏保管能力，並延伸連接沿海進口樞紐與內陸製造地和臨床試驗中心的多模態走廊。該地區也高度重視關鍵治療藥物的隔日達和當日達配送模式，這推動了對檢驗的溫控專用航空貨運服務和本地「最後一公里」配送專家的需求。

對於服務生物製藥產業客戶的物流供應商而言，一體化的全球規模、專業的低溫運輸技術、檢驗的本地基礎設施和戰略夥伴關係，才是賦予他們決定性競爭優勢的關鍵。

該產業的競爭格局由全球物流整合商、專業低溫運輸營運商以及融入醫藥分銷生態系統的服務供應商組成。市場領導，檢驗多模態臨床試驗物流和高優先級末端配送服務的利基供應商可以透過提供客製化處理方案、快速反應團隊以及在特定治療領域的深厚專業知識，確立其領先地位。

為物流主管提供切實可行的建議，包括：整合可視性、檢驗的基礎設施、海關專業知識和基於風險的商業模式，以保護對溫度敏感的物流流動。

產業領導者應採用以四項互補優先事項為核心的策略框架，以確保產品完整性和業務永續營運。首先，透過實施可互通的遙測技術、數位化監管鏈系統和集中式控制塔，實現端到端的可視性，從而實現預測性路線規劃和快速異常管理。這種方法可以縮短停留時間，提高監管審計的準備程度，並增強複雜多模態物流的決策能力。其次，優先投資於檢驗基礎設施，例如區域冷庫、低溫處理中心和認證包裝材料庫，以支援在不同溫度條件下擴充性且合規的配送。

透過高度透明的混合方法研究，結合對從業者的訪談、情境分析和營運案例研究，我們獲得了關於物流能力差距和解決方案的可重複見解。

本研究途徑結合了對行業相關人員的初步調查以及對營運實踐的系統性回顧，以得出基於證據的見解。初步研究包括對供應鏈負責人、低溫運輸工程師、品質保證經理和物流服務供應商進行結構化訪談，以收集關於處理流程、包裝驗證和異常管理的第一手觀點。這些定性資訊與已記錄的監管指南和公開的最佳實踐進行交叉比對，以確保分析的嚴謹性和可操作性。

總之，綜合討論強調了實現穩健的藥品分銷需要綜合可視性、檢驗的溫度控制、海關清關能力和戰略夥伴關係。

總而言之，生技藥品、血液製品和疫苗的有效分銷需要對物流策略進行全面重組，轉向以可視性為中心、檢驗且本地化最佳化的解決方案。持續的關稅和監管壓力正在加速本地化和近岸外包的趨勢，同時也提升了清關能力和綜合服務交付的價值。能夠將多模態專業知識與檢驗的包裝、低溫處理能力和綜合品質檢驗相結合的供應商，最能滿足現代治療藥物分銷的嚴苛要求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製藥物流市場：依產品類型分類

  • 生物製藥
  • 血液製品
  • 疫苗

第9章：生物製藥物流市場：依服務類型分類

  • 低溫運輸包裝
  • 報關
  • 轉發
  • 倉儲/配送
  • 附加價值服務
    • 套件組裝服務
    • 標籤服務
    • 品質檢驗

第10章：以運輸方式分類的生物製藥物流市場

  • 航空
  • 鐵路
  • 土地
  • 海上運輸

第11章：依溫度要求分類的生物製藥物流市場

  • 環境的
  • 極低溫度
  • 冰凍
  • 冷藏

第12章：生物製藥物流市場：依最終用戶分類

  • 診所
  • CRO（藥物研發合約研究組織）
  • 醫院
  • 製藥公司
  • 研究機構

第13章：生物製藥物流市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物製藥物流市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物製藥物流市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物製藥物流市場

第17章：中國生物製藥物流市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agility Public Warehousing Company KSCP
  • Air Canada Cargo Inc.
  • Almac Group Limited
  • AmerisourceBergen Corporation
  • Biocair Limited
  • CH Robinson Worldwide, Inc.
  • Cardinal Health, Inc.
  • CEVA Logistics AG
  • Cryoport Inc.
  • DB Schenker
  • Deutsche Post DHL Group
  • DSV Panalpina A/S
  • FedEx Corporation
  • GEODIS SA
  • Kerry Logistics Network Limited
  • Kuehne+Nagel International AG
  • MNX Global Logistics LLC
  • Movianto Group
  • Nippon Express Co., Ltd.
  • PCI Pharma Services Holdings LLC
  • QuickSTAT Global Life Science Logistics Inc.
  • SF Express Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • United Parcel Service, Inc.
  • World Courier Inc.
Product Code: MRR-437D459587C9

The Bio-Pharmaceutical Logistics Market was valued at USD 18.71 billion in 2025 and is projected to grow to USD 20.69 billion in 2026, with a CAGR of 11.76%, reaching USD 40.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.71 billion
Estimated Year [2026] USD 20.69 billion
Forecast Year [2032] USD 40.77 billion
CAGR (%) 11.76%

An incisive introduction to the contemporary bio-pharmaceutical logistics environment highlighting technological convergence, regulatory intensity, and strategic imperatives for resilient supply chains

The bio-pharmaceutical logistics landscape is confronting an era of intensifying complexity driven by scientific advances, regulatory scrutiny, and shifting geopolitical dynamics. Companies that move investigational products, biologics, blood products, and vaccines face heightened demands for exacting temperature control, traceability, and compliance across increasingly bifurcated global networks. Consequently, logistics leaders must reconcile the dual imperatives of minimizing risk to product integrity while maintaining speed and cost-efficiency in distribution and clinical supply chains.

Moreover, the industry is experiencing a convergence of technology adoption, such as digital temperature monitoring and blockchain-enabled provenance tracking, with operational redesigns including nearer-shore manufacturing and multi-modal transport strategies. This convergence is reshaping the playbook for providers and shippers alike, as service models evolve to integrate value-added functions such as kitting, labeling, and quality inspection directly into distribution workflows. As a result, stakeholders across the value chain are rethinking partnerships, contracting frameworks, and capital allocation to support resilient, compliant pathways from manufacturing to patient.

In this context, strategic foresight and operational dexterity become the differentiators. Leaders must prioritize data-driven visibility, regulatory harmonization, and contingency capacity in order to mitigate disruptions. The following sections unpack the transformative shifts, tariff-driven headwinds, segmentation nuances, regional dynamics, and actionable recommendations that together define the contemporary bio-pharmaceutical logistics imperative.

How temperature assurance, regulatory convergence, digital control towers, and sustainability pressures are jointly transforming bio-pharmaceutical logistics into capability-driven service models

The industry is undergoing several transformative shifts that are recalibrating expectations for speed, security, and quality in bio-pharmaceutical logistics. First, temperature-sensitive handling has moved from a compliance checkbox to a strategic capability, with stakeholders demanding end-to-end cold chain assurance that spans cryogenic, frozen, refrigerated, and ambient requirements. This shift is driving investment not only in insulated packaging and active-controlled containers but also in real-time telemetry that provides granular visibility across every transport leg.

Second, regulatory harmonization and inspection rigor are increasing simultaneously, prompting operators to formalize standardized documentation, calibration protocols, and digital audit trails. This trend is interlinked with the rise of decentralized clinical trials and the need to move smaller, higher-value shipments to geographically dispersed sites with consistent quality controls. Consequently, logistics providers are layering value-added services-ranging from kitting and labeling to in-line quality inspection-closer to point-of-care or regional distribution centers.

Third, technology adoption is accelerating systemic improvements in routing, customs clearance, and exception management. Predictive analytics and integrated control towers are enabling dynamic decisioning that reduces dwell time at borders and optimizes mode selection between air, road, rail, and sea based on cost, speed, and product fragility. Finally, sustainability considerations and cost pressures are incentivizing modal shifts and packaging innovation, as stakeholders seek lower-carbon pathways without compromising the integrity of biologics and vaccines. Taken together, these shifts represent a reorientation from transactional logistics to a consultative, capability-driven model that prioritizes product safety and commercial continuity.

The multifaceted cumulative effects of recent tariff dynamics reshaping sourcing, modal choices, customs expertise requirements, and regional infrastructure investment in bio-pharmaceutical logistics

The imposition and evolution of tariffs in the United States through 2025 have had a cumulative effect on bio-pharmaceutical logistics that extends beyond headline duty rates to influence routing decisions, supplier selection, and inventory posture. Rising tariff burdens increase landed costs and incentivize companies to reevaluate sourcing footprints and modal mixes to preserve access to critical manufacturing components and finished biologics. As a result, many stakeholders are exploring supply chain segmentation by criticality of product and time-sensitivity to determine which flows justify premium air transport and which can be consolidated and routed via lower-cost sea or rail corridors.

In practice, tariff-driven adjustments translate into longer transit leg optimization exercises and increased reliance on customs clearance expertise. Logistics providers with embedded customs brokerage capabilities and hardened documentation workflows are capturing higher-value roles because they reduce clearance friction and minimize the risk of temperature excursions due to border delays. Furthermore, tariffs have catalyzed nearshoring and regionalization strategies that compress cross-border transit times; this shift increases demand for regional cold storage and distribution nodes and stimulates investment in specialized infrastructure such as validated storage rooms and cryogenic handling facilities.

Another consequential impact is the reconfiguration of contract terms and insurance structures, where shippers seek clearer allocation of tariff risk and expedited claims procedures for temperature-related loss. In tandem, procurement teams are pushing for greater transparency in landed cost models that account for duties, surcharges, and compliance obligations. Altogether, tariffs have accentuated the need for integrated trade compliance, adaptive logistics planning, and strategic partnerships that can absorb regulatory volatility while safeguarding the quality and continuity of biopharmaceutical flows.

Detailed segmentation analysis revealing how service scope, transport modes, temperature classes, product types, and end-user expectations jointly define operational requirements and strategic investments

A granular segmentation lens reveals distinct demand patterns, operational requirements, and commercial opportunities across service types, transport modes, temperature classes, product categories, and end users. Based on service type, the ecosystem encompasses Cold Chain Packaging, Customs Clearance, Freight Forwarding, Storage And Distribution, and Value Added Services, where Value Added Services itself includes Kitting Services, Labeling Services, and Quality Inspection; this distribution of functions underscores the imperative for providers to bundle technical handling with compliance and product preparation capabilities. When examined by mode of transport, shipments traverse Air, Rail, Road, and Sea corridors, each offering tradeoffs between speed, cost, and exposure to environmental variation, and requiring bespoke packaging strategies and contingency planning.

Temperature requirement segmentation further differentiates operational practices: Ambient flows demand minimal thermal control but rigorous contamination safeguards, Refrigerated shipments require validated temperature windows and continuous monitoring, Frozen transport imposes stricter containerization and holding-time constraints, and Cryogenic logistics introduces specialized equipment and handling protocols for ultra-low temperatures. Product type segmentation-covering Biologics, Blood Products, and Vaccines-adds another layer of differentiation, since biologics and vaccines frequently necessitate batch-level traceability, expedited customs processing, and prioritized transport lanes, while blood products often require rapid, localized distribution networks and stringent donor-origin tracking.

Finally, end user segmentation including Clinics, Contract Research Organizations, Hospitals, Pharmaceutical Companies, and Research Institutes determines service expectations and SLA structures. Clinics and hospitals demand reliability and predictable last-mile performance, contract research organizations and research institutes prioritize secure handling for clinical trial materials, and pharmaceutical companies typically seek integrated solutions that combine global forwarding, validated storage, and quality oversight. Synthesizing these segmentation dimensions clarifies where investments in technology, validated assets, and specialized personnel will create the greatest operational leverage and commercial differentiation.

How differing infrastructure investments, regulatory complexity, and clinical growth across the Americas, Europe Middle East & Africa, and Asia-Pacific are driving regional specialization and capacity build-out

Regional dynamics are shaping differential demand patterns, infrastructure development, and regulatory harmonization efforts across major geographies. In the Americas, investments are concentrated on scaling regional cold storage capacity and expanding multi-modal corridors that link coastal import hubs with inland manufacturing and clinical trial centers. This region is also characterized by a pronounced focus on single-day and same-day delivery models for critical therapies, which drives demand for dedicated air freight services and local last-mile specialists capable of validated handoffs and temperature assurance.

Europe, Middle East & Africa presents a complex overlay of regulatory regimes and distribution geographies. This region is investing in interoperable digital documentation and customs data exchange to reduce cross-border friction, while advanced European markets emphasize sustainability alongside high regulatory standards, spurring demand for packaging innovation and consolidated distribution platforms. Emerging markets within the region add another layer of operational complexity, where constrained cold infrastructure and variable road quality require hybrid solutions that combine centralized cold hubs with robust last-mile packaging and monitoring.

Asia-Pacific is witnessing rapid expansion of biologics manufacturing capabilities and an uptick in clinical activity, which together are driving investments in validated storage, air freight capacity, and cold chain packaging innovation. Cross-border intra-regional trade is increasingly important, prompting logistics providers to build regional networks that minimize transit times and leverage rail and sea corridors as cost-effective alternatives to long-haul air. Across all regions, regulatory synchronization, digital visibility, and investment in validated assets are the primary levers for reducing product risk and enabling scalable distribution of temperature-sensitive therapies.

Why integrated global scale, specialized cold chain expertise, validated local infrastructure, and strategic partnerships are the decisive competitive levers for logistics providers serving biopharmaceutical customers

Competitive dynamics in the sector are shaped by a mixture of global logistics integrators, specialized cold chain operators, and service providers embedded within pharmaceutical distribution ecosystems. Market leaders that combine global forwarding scale with temperature-controlled asset ownership are increasingly favored for complex global programs because they can offer validated storage, multi-modal routing, and integrated customs clearance under a single contractual umbrella. Conversely, niche providers that concentrate on clinical trial logistics or high-acuity last-mile services can command premium positioning by delivering tailored handling protocols, rapid response teams, and deep therapeutic-area expertise.

Partnership models are also evolving, as pharmaceutical manufacturers seek closer collaboration with logistics partners through long-term contracts, shared-risk frameworks, and jointly developed quality systems. Technology partnerships that enable telemetry, chain-of-custody documentation, and centralized control towers are particularly valued for their ability to reduce dwell time and provide auditable data for regulatory inspections. Moreover, companies that invest in local validated infrastructure-such as GMP-compliant storage rooms and cryogenic handling centers-are better positioned to capture the growing volume of regionally distributed biologics and clinical supplies.

Finally, consolidation and selective alliances are reshaping service offerings, with some global integrators forming strategic relationships with specialized cold chain specialists to extend capability breadth without diluting quality controls. These alliances create differentiated propositions by combining operational scale, regulatory know-how, and domain-specific handling expertise, thereby addressing the full spectrum of requirements from investigational product distribution to commercial biologic rollouts.

Actionable recommendations for logistics executives to embed visibility, validated infrastructure, customs expertise, and risk-aligned commercial models to protect temperature-sensitive flows

Industry leaders should adopt a strategic framework oriented around four complementary priorities to safeguard product integrity and commercial continuity. First, embed end-to-end visibility by deploying interoperable telemetry, digital chain-of-custody systems, and centralized control towers that enable predictive routing and rapid exception management. This approach reduces dwell time, enhances regulatory audit readiness, and improves decision-making across complex multi-modal flows. Second, prioritize modular investments in validated infrastructure such as regional cold storage, cryogenic handling centers, and certified packaging pools to support scalable, compliant distribution across diverse temperature profiles.

Third, strengthen trade compliance and customs brokerage capabilities through dedicated expertise and standardized documentation workflows. Robust customs performance mitigates the tariff and clearance-driven delays that can compromise temperature-sensitive shipments and disrupt clinical timelines. Fourth, align commercial models with strategic risk sharing by negotiating transparent terms that account for tariff exposure, expedited handling requirements, and claim settlement processes. These contractual structures incentivize continuous quality improvement and create clarity on liability for temperature excursions.

Collectively, these priorities should be operationalized through cross-functional governance that integrates procurement, quality assurance, cold chain engineering, and commercial teams. By instituting performance metrics tied to product integrity outcomes, response times, and documentation accuracy, organizations will be better positioned to convert logistical resilience into measurable business advantage.

Transparent mixed-method research approach combining practitioner interviews, scenario analysis, and operational case studies to derive reproducible insights into logistics capability gaps and solutions

The research approach combined primary engagement with industry stakeholders and a systematic review of operational practices to produce evidence-based insights. Primary engagement included structured interviews with supply chain leaders, cold chain engineers, quality assurance managers, and logistics service providers to capture first-hand perspectives on handling protocols, packaging validation, and exception management. These qualitative inputs were triangulated with documented regulatory guidance and publicly available operational best practices to ensure analytical rigor and practical relevance.

Analytical methods employed scenario analysis to explore the operational implications of tariff shifts and modal reconfigurations, while comparative case studies highlighted successful implementations of regional cold infrastructure and control tower architectures. Data synthesis focused on operational levers-such as packaging performance, telemetry penetration, customs clearance cycles, and validated storage capacity-rather than on speculative market sizing, enabling a pragmatic assessment of capability gaps and investment priorities. Throughout, the methodology emphasized reproducibility and transparency, with clear documentation of interview protocols, validation checks, and assumptions underpinning scenario narratives.

This mixed-methods design ensures that conclusions rest on both practitioner experience and observable operational trends, providing a robust foundation for strategic decision-making in bio-pharmaceutical logistics.

Concluding synthesis emphasizing the necessity of integrated visibility, validated temperature control, customs competence, and strategic partnerships to enable resilient therapeutic distribution

In conclusion, the effective distribution of biologics, blood products, and vaccines demands a holistic realignment of logistics strategy toward visibility-driven, validated, and regionally tuned solutions. Persistent tariff and regulatory pressures are accelerating regionalization and nearshoring trends while simultaneously elevating the value of customs competence and integrated service offerings. Providers that can combine multi-modal routing expertise with validated packaging, cryogenic handling capabilities, and embedded quality inspection will be best positioned to meet the stringent demands of modern therapeutic distribution.

Decision-makers must therefore prioritize investments that reduce exposure to border delays, enhance temperature assurance across ambient to cryogenic classes, and institutionalize digital traceability to support regulatory inspections and rapid recalls. By adopting modular infrastructure investments, forging technology-enabled partnerships, and aligning commercial terms to reflect shared risk, stakeholders can transform logistical complexity into a strategic asset that supports faster patient access, improved clinical trial integrity, and more resilient commercial supply chains. The path forward requires coordinated action across procurement, operations, quality, and commercial teams to translate these insights into measurable operational improvements.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bio-Pharmaceutical Logistics Market, by Product Type

  • 8.1. Biologics
  • 8.2. Blood Products
  • 8.3. Vaccines

9. Bio-Pharmaceutical Logistics Market, by Service Type

  • 9.1. Cold Chain Packaging
  • 9.2. Customs Clearance
  • 9.3. Freight Forwarding
  • 9.4. Storage And Distribution
  • 9.5. Value Added Services
    • 9.5.1. Kitting Services
    • 9.5.2. Labeling Services
    • 9.5.3. Quality Inspection

10. Bio-Pharmaceutical Logistics Market, by Mode Of Transport

  • 10.1. Air
  • 10.2. Rail
  • 10.3. Road
  • 10.4. Sea

11. Bio-Pharmaceutical Logistics Market, by Temperature Requirement

  • 11.1. Ambient
  • 11.2. Cryogenic
  • 11.3. Frozen
  • 11.4. Refrigerated

12. Bio-Pharmaceutical Logistics Market, by End User

  • 12.1. Clinics
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals
  • 12.4. Pharmaceutical Companies
  • 12.5. Research Institutes

13. Bio-Pharmaceutical Logistics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bio-Pharmaceutical Logistics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bio-Pharmaceutical Logistics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bio-Pharmaceutical Logistics Market

17. China Bio-Pharmaceutical Logistics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agility Public Warehousing Company K.S.C.P.
  • 18.6. Air Canada Cargo Inc.
  • 18.7. Almac Group Limited
  • 18.8. AmerisourceBergen Corporation
  • 18.9. Biocair Limited
  • 18.10. C.H. Robinson Worldwide, Inc.
  • 18.11. Cardinal Health, Inc.
  • 18.12. CEVA Logistics AG
  • 18.13. Cryoport Inc.
  • 18.14. DB Schenker
  • 18.15. Deutsche Post DHL Group
  • 18.16. DSV Panalpina A/S
  • 18.17. FedEx Corporation
  • 18.18. GEODIS S.A.
  • 18.19. Kerry Logistics Network Limited
  • 18.20. Kuehne + Nagel International AG
  • 18.21. MNX Global Logistics LLC
  • 18.22. Movianto Group
  • 18.23. Nippon Express Co., Ltd.
  • 18.24. PCI Pharma Services Holdings LLC
  • 18.25. QuickSTAT Global Life Science Logistics Inc.
  • 18.26. SF Express Co., Ltd.
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. United Parcel Service, Inc.
  • 18.29. World Courier Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BLOOD PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BLOOD PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY BLOOD PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COLD CHAIN PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COLD CHAIN PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COLD CHAIN PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CUSTOMS CLEARANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CUSTOMS CLEARANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CUSTOMS CLEARANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FREIGHT FORWARDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FREIGHT FORWARDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FREIGHT FORWARDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY STORAGE AND DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY STORAGE AND DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY STORAGE AND DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY KITTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY KITTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY KITTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY QUALITY INSPECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY QUALITY INSPECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY QUALITY INSPECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY ROAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY ROAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY ROAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AMBIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AMBIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY AMBIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CRYOGENIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CRYOGENIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CRYOGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REFRIGERATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REFRIGERATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REFRIGERATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY VALUE ADDED SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY MODE OF TRANSPORT, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BIO-PHARMACEUTICAL LOGISTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)